Carevive, a health IT startup cofounded by oncology nurses, landed a deal in early June with global electronic health record vendor Cerner, positioning the Philadelphia and Miami-based company to significantly expand its business. The company’s software is designed to efficiently produce comprehensive care plans for patients and physicians.
Cerner will integrate Carevive’s patient care planning software within its PowerChart Oncology product.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Carevive CEO Madelyn Herzfeld explained in a phone interview the significance of the deal.
“The value of this collaboration is twofold. It’s a great care distribution channel with a major global EMR vendor. It is also important because it is where medicine needs to go. It helps to improve the quality of Carevive’s offering with data and workflow integration. It’s what physicians and patients need.
Carevive works with health systems, cancer centers and pharma companies using HL7 — the company’s software is EMR-agnostic.
The health IT business started out in 2013 with a focus on survivorship care plans, but has grown considerably in the past few years. Herzfeld, who cofounded the company with Carrie Stricker, Chief Clinical Officer, noted that they realized that patient preferences and patients voices needed to be better integrated into their care plans when they were diagnosed at the start of their treatment, not at the survivorship stage of their care.
Attend MedCity CONVERGE to hear from healthcare innovators like Carrie Stricker, cofounder of Carevive, and other experts. Use promo code MCNPOST to save $50. Register now.
The software helps care teams to personalize treatment decision-making and standardize symptom assessment when patients are in “active treatment” and in the survivorship period based on relevant clinical, patient-reported health data, and clinical evidence, the statement said.
The data include diagnosis, treatment, symptom experience and risk category, much of it informed from patient-reported data. The data are factored into auto-generated, personalized care plans that are delivered to patients when they meet with oncology physicians and nurses.
These assessments change to reflect the patient’s evolving health status. Guidance offered in the Carevive care plans are prepared and continuously maintained by more than 1,000 oncology clinical subject matter experts who leverage over 25 professional society guidelines, according to Carevive’s website.
Clinician dashboards highlight patient reported outcomes and clinical data, with evidenced-based guidelines to make shared decision making easier.
Carevive’s technology conforms with the Oncology Care Model, a five-year program rolled out by the Centers for Medicare and Medicaid Innovation last year. The payment delivery model is intended to improve the effectiveness and efficiency of specialty care.
Don Bisbee, Cerner senior vice president, said in a news release that integrating Carevive’s and Cerner’s platforms equip providers with the information they need deliver patient-centered care.
“Person-centered care delivery models are essential as the market shifts from volume to value-based care, and collaborating with Carevive will give our clients access to comprehensive oncology care that can help improve patient engagement, treatment decision-making and overall care management,” he said.
Last fall, Carevive closed a $7.2 million Series B round to expand its product offering, support its rapidly growing customer base, and to build its sales business. Investors in the round included HLM Venture Partners and Long River Ventures.
The company’s customers span health systems and pharma including Sidney Kimmel Cancer Center at Jefferson University Hospitals, Penn Medicine Virtua Cancer Program, The Hartford HealthCare Cancer Institute, Indiana University Health Cancer Center. U.S. pharma clients include Genentech BioOncology, Novartis, Celgene Corporation, Takeda Pharmaceutical Company, Abbott, and Amgen.
